Am Fam Physician. 2023;108(5):online
Author disclosure: No relevant financial relationships.
Details for This Review
Study Population: 5,831 patients with depression and a history of stroke
Efficacy End Points: Remission of depression at the end of treatment; inadequate response to treatment (less than 50% reduction in scale scores at the end of treatment)
Harm End Points: Adverse events from therapy such as death, neurologic events, and gastrointestinal effects
| Benefits | Harms |
|---|---|
| 1 in 6 had remission of depression at the end of pharmacologic treatment, compared with placebo 1 in 3 in the pharmacologic treatment group had reduced risk of inadequate treatment response, compared with placebo group 1 in 7 had remission of depression from psychological therapy, compared with usual care or attention control 1 in 7 had remission of depression from noninvasive brain stimulation plus pharmacologic treatment, compared with pharmacologic treatment plus sham stimulation or usual care | 1 in 11 experienced neurologic adverse events from pharmacologic treatment, compared with placebo 1 in 8 experienced gastrointestinal adverse events from pharmacologic treatment, compared with placebo |
Already a member/subscriber?
Log In
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
Purchase Access:
Learn More
